- Home
- SEED vs INDP Comparison
SEED vs INDP Comparison
Compare SEED & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEED
- INDP
- Stock Information
- Founded
- SEED 1997
- INDP 2000
- Country
- SEED China
- INDP United States
- Employees
- SEED N/A
- INDP N/A
- Industry
- SEED Farming/Seeds/Milling
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- SEED Consumer Staples
- INDP Health Care
- Exchange
- SEED Nasdaq
- INDP Nasdaq
- Market Cap
- SEED 12.1M
- INDP 10.2M
- IPO Year
- SEED N/A
- INDP N/A
- Fundamental
- Price
- SEED $1.83
- INDP $0.84
- Analyst Decision
- SEED
- INDP Strong Buy
- Analyst Count
- SEED 0
- INDP 2
- Target Price
- SEED N/A
- INDP $8.50
- AVG Volume (30 Days)
- SEED 38.9K
- INDP 25.3K
- Earning Date
- SEED 02-19-2025
- INDP 03-12-2025
- Dividend Yield
- SEED N/A
- INDP N/A
- EPS Growth
- SEED N/A
- INDP N/A
- EPS
- SEED 1.21
- INDP N/A
- Revenue
- SEED $16,516,031.00
- INDP N/A
- Revenue This Year
- SEED N/A
- INDP N/A
- Revenue Next Year
- SEED N/A
- INDP N/A
- P/E Ratio
- SEED $1.51
- INDP N/A
- Revenue Growth
- SEED 64.93
- INDP N/A
- 52 Week Low
- SEED $1.37
- INDP $0.81
- 52 Week High
- SEED $6.38
- INDP $3.10
- Technical
- Relative Strength Index (RSI)
- SEED 29.66
- INDP 39.07
- Support Level
- SEED $1.64
- INDP $0.86
- Resistance Level
- SEED $2.00
- INDP $1.06
- Average True Range (ATR)
- SEED 0.16
- INDP 0.08
- MACD
- SEED -0.01
- INDP 0.00
- Stochastic Oscillator
- SEED 29.23
- INDP 12.80
About SEED Origin Agritech Limited
Origin Agritech Ltd is a Chinese agricultural technology company. In crop seed biotechnologies, the company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.